Disease-modifying anti-rheumatic drugs

Phase 3Small molecule

Disease-modifying anti-rheumatic drugs is one of 67 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisCompleted

COVID-19Active, not recruiting

Rheumatoid ArthritisPhase 3

Completed

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

309 competitors in COVID-19

#DrugCompanyPhaseTrials

Disease-modifying anti-rheumatic drugs

Roche

Phase 3

1 2

Glucocorticoid

AbbVie

Preclinical

1 3

SARS-COV-2 VACCINE

Moderna

Preclinical

2 4

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 5

Blood Taken

HHospices Civils de Lyon

Preclinical

1 6

Sivelestat Sodium

TThe First Hospital of Jilin University

Preclinical

1 7

Standard Preparation

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

1 8

Immunosuppressive

Chiesi Farmaceutici S.p.A.

Preclinical

1 9

Serology

UUniversity Hospital Center of Martinique

Preclinical

3 10

Nadroparin

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)

Completed· Astellas logo

Astellas·Phase 3·NCT03660059·385 enrolled

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01194414·1,262 enrolled

L-carnitine Supplementation in Rheumatoid Arthritis Patients

Recruiting·GGerman University in Cairo·Phase 2·NCT06753565·60 enrolled

COVID-191 trial

Predictive Factors for COVID-19 in Rheumatology

Unknown status·FFundación Santa Fe de Bogota··NCT04567576·150 enrolled

Tocilizumab1 trial

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Completed· Roche logo

Roche·Phase 3·NCT00720798·2,067 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Disease-modifying anti-rheumatic drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Disease-modifying anti-rheumatic drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Disease-modifying anti-rheumatic drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Disease-modifying anti-rheumatic drugs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis3 trials

COVID-191 trial

Tocilizumab1 trial

References

Drug Info

Quick Facts

Related News